NEO

In the past six months, NeoGenomics, Inc. (NEO) stock increased by 143.76% between September 26, 2025, and September 25, 2026. The company reported strong Q2 2026 financial results on July 28, 2026, with EPS of $0.05 and revenue of $201.7 million, leading to a slight lift in full-year 2026 revenue guidance. Further positive news included receiving Medicare coverage for its RaDaR ST assay on August 26, 2026, and the integration of its oncology testing portfolio with Epic Aura on April 23, 2026. However, on October 6, 2026, the stock price dropped over 12% following the announcement of executive leadership transitions, with Warren Stone appointed as the new CEO effective January 4, 2027, replacing Tony Zook. This decline occurred despite preliminary Q3 2026 revenue of approximately $209 million, which modestly beat expectations and included strong 28% year-over-year growth in next-generation sequencing services, with investors reacting negatively to the company's unprofitable status and management uncertainty.